Diffuse refractory esophageal spasm with excellent response to treatment with sildenafil

Author(s):  
Marina Puya Gamarro ◽  
María del Carmen López Vega ◽  
Isabel María Méndez Sánchez
Author(s):  
Susan Shafiei ◽  
Mehrdokht Sadrolodabaei ◽  
Atena Aghaei ◽  
Narjess Ayati ◽  
Samira Zare Namdar ◽  
...  

Background: Familial NMTCs are supposed to be more aggressive and require more frequent treatment compared to non-familial thyroid cancer. Objectives: This matched case-control study aimed to compare the response to treatment between the matched case-control groups of familial and sporadic NMTC. Methods: This is a retrospective study in patients with familial NMTC (at least one other first-degree relative involved) who were treated with surgery, followed by radio-iodine therapy (RIT) without consideration of its familial origin. Response to treatment was compared between familial NMTC and age, sex, and TNM stage-matched non-familial NMTC (control group). Response to treatment was assessed one and two years after RIT, and time to excellent response was identified. Results: Out of 2,944 NMTC patients, 81 (2.75%) patients had familial NMTC. We compared 66 patients with familial NMTC and 66 sporadic NMTC patients. There was no significant difference in first thyroglobulin, initial and accumulative iodine dose, and additional treatments (additional surgery and radiotherapy) between patients and controls. Although no significant difference was noted in one and two years’ responses to treatment between the case and control groups, familial NMTC patients required more time to achieve excellent response (26.7 ± 24.9 versus 15.9 ± 9.0 months, P = 0.01). No significant difference was noted between familial NMTC patients with two or more than two involved relatives. Conclusions: Our study showed that if patients with familial NMTCs were treated in the same way as non-familial patients, the time to excellent response would be significantly longer, even when they have only one other involved relative.


1997 ◽  
Vol 3 (2) ◽  
pp. 296-296
Author(s):  
Falih M. Al Obadi ◽  
Jinan I. Mobarak ◽  
Abdullah M. Jawad

Forty-four [44] patients with severe renal colic were studied for their response to 500 mg injectable aspirin [Aspegic] administered intravenously twice daily for two days. It was found that 22.7% reported complete relief from pain after the first injection and 72.7% showed various degrees of improvement. In the overall assessment at the end of treatment, 63.6% showed an excellent response. Two patients did not show any response to treatment. Nineteen patients [43.2%] had felt or seen the stone pass out in urine, and none experienced any major adverse effects. Aspegic could be a useful drug in emergency treatment of severe renal colic


2018 ◽  
Vol 87 (6) ◽  
pp. 337-341
Author(s):  
J. Declercq

Neutrophilic and ulcerative dermatitis is reported in a mixed breed dog. The condition was considered to be an atypical case of pyoderma gangrenosum. Clinically, it had a more superficial ulceration, a more pronounced pustular component and lacked the characteristic cutaneous pain and tenderness of the lesions. The diagnosis of pyoderma gangrenosum was made as a diagnosis of exclusion. The dog showed an excellent response to treatment with ciclosporin (Cyclavance, Virbac, Leuven, Belgium).


2019 ◽  
Vol 37 (8_suppl) ◽  
pp. 111-111
Author(s):  
Carlo Capalbo ◽  
Marco Filetti ◽  
Giorgia Scafetta ◽  
Paolo Marchetti ◽  
Armando Bartolazzi

111 Background: Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology with objective responses registered in several tumors. However reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of patients candidate to immunotherapy. In NSCLC setting, the pleiotropic molecules Galectin 1 and 3 regulate apoptosis and tumor immune-escape and are in the right position to play as predictive marker in anti-PD1 based immunotherapy. Methods: 27 consecutive patients with non small cell lung cancer (NSCLC) stage IV, treatment-naive, selected on the basis of PD-L1 tumor proportion score (TPS) ≥ 50 % were considered for immunotherapy with anti PD-1 antibodies as a first-line treatment. Patients assessments were conducted at baseline and after 3 cycles of therapy (week 12) and classified according to immune-related response criteria (iRECIST). Immunohistochemical analysis was performed on primary tumor biopsies before treatment in order to evaluate Gal-1 and Gal-3 expression both in cancer cells and tumor interstitium. Tumors were grouped in 2 different classes depending on the expression level of these molecules. Results: In our preliminary data there seems to be a strong correlation between the responses to anti-PD-1 treatment and a low-intermediate expression of intratumoral Gal-3 and interstitial Gal-1. In fact, all patients in the intratumoral Gal-3 low-intermediate expression group had an excellent response to immunotherapic treatment (10/10 patients), while 15/17 patients with high intracellular Gal-3 expression had clinical and radiographic progression of the disease after only three cycles of treatment, despite the high expression of PD-L1. In contrast, 8/11 patients with a low-intermediate interstitial expression of Gal-1 had an excellent response to treatment, whereas in the group with high interstitial expression of Gal-1, the response rate was drastically lower (5/15 patients). Conclusions: The expression of interstitial Gal-1 protein and intratumoral Gal-3 protein appear to be a good candidates as predictive markers of response to immunotherapy.


2021 ◽  
pp. 004947552110343
Author(s):  
Laxmikant Ramkumarsingh Tomar ◽  
Dhrumil Jatinbhai Shah ◽  
Utkarsh Agarwal ◽  
Atul Gogia ◽  
Anshu Rohatgi ◽  
...  

Opsoclonus myoclonus syndrome secondary to scrub typhus infection is a rare clinical entity. Hence, it is important to know its clinical manifestations and complications, so that it can be properly managed. We report a 28-year-old female whose initial manifestation was only fever, which subsided in four days. Two days later, she developed opsoclonus myoclonus syndrome. This was managed with doxycycline and clonazepam, but as it persisted, intravenous immunoglobulin was added. She showed excellent response to treatment.


2010 ◽  
Vol 5 (8) ◽  
pp. 1301-1302 ◽  
Author(s):  
Martin Fehr ◽  
Max Kuhn ◽  
Kurt Mayer ◽  
Barbara Padberg ◽  
Ulrich Ulmer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document